WASHINGTON -A U.S. judge on Friday barred Martin Shkreli from the pharmaceutical industry for life and ordered him to pay $64.6 million after he famously raised the price of Daraprim and fought to block generic competitors.
Shkreli drew notoriety in 2015 after hiking Daraprim's price overnight to $750 per tablet from $17.50. The drug treats toxoplasmosis, a parasitic infection that threatens people with weakened immune systems. She said the Daraprim scheme was "particularly heartless and coercive," and a lifetime industry ban was needed because of the "real danger" that Shkreli could become a repeat offender.
Neither Shkreli's lawyers nor the FTC immediately responded to requests for comment. The nonjury trial was held last month.Vyera was founded in 2014 as Turing Pharmaceuticals, and acquired Daraprim from Impax Laboratories Inc in 2015.
So we can bar a private citizen from a private industry for the damage he caused to it and the people his decisions negatively affected but we cant bar a private citizen from public office for attempting to overthrow the government